Patents by Inventor Amara Seng

Amara Seng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED REGULATORY T CELLS
    Publication number: 20220008474
    Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 13, 2022
    Inventors: Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko
  • Engineered regulatory T cells
    Patent number: 11160832
    Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: November 2, 2021
    Assignees: The Children's Mercy Hospital, The University of Kansas
    Inventors: Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko
  • ENGINEERED REGULATORY T CELLS
    Publication number: 20210008111
    Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Inventors: Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko